• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: comment.

作者信息

Noble S, Alikhan R, Robbins A, Macbeth F, Hood K

机构信息

Cardiff University, Cardiff, UK.

University Hospital of Wales, Cardiff, UK.

出版信息

J Thromb Haemost. 2017 Mar;15(3):590-591. doi: 10.1111/jth.13594. Epub 2017 Feb 3.

DOI:10.1111/jth.13594
PMID:27992116
Abstract
摘要

相似文献

1
Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: comment.活动性癌症血栓栓塞结局的预测因素：肺癌患者中Khorana评分的验证：评论
J Thromb Haemost. 2017 Mar;15(3):590-591. doi: 10.1111/jth.13594. Epub 2017 Feb 3.
2
Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply.活动性癌症血栓栓塞结局的预测因素：肺癌患者中Khorana评分的验证：回复
J Thromb Haemost. 2017 Mar;15(3):591-592. doi: 10.1111/jth.13592. Epub 2017 Feb 3.
3
Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.霍拉纳评分：肺腺癌患者早期死亡率的新预测指标。
Clin Appl Thromb Hemost. 2018 Nov;24(8):1347-1351. doi: 10.1177/1076029618777153. Epub 2018 May 27.
4
Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.识别晚期肺癌患者静脉血栓栓塞风险因素并验证 Khorana 评分：基于多中心前瞻性 Rising-VTE/NEJ037 研究数据。
Int J Clin Oncol. 2023 Jan;28(1):69-78. doi: 10.1007/s10147-022-02257-y. Epub 2022 Nov 10.
5
A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.改良的 Khorana 评分作为预测新诊断的晚期肺癌患者静脉血栓栓塞风险的评估工具。
J Thromb Thrombolysis. 2021 Oct;52(3):898-903. doi: 10.1007/s11239-021-02396-5. Epub 2021 Feb 18.
6
COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.COMPASS-CAT 与 Khorana 风险评估模型在化疗和/或免疫治疗的非小细胞肺癌患者中的比较，CK-RAM 研究。
J Thromb Thrombolysis. 2023 Oct;56(3):447-453. doi: 10.1007/s11239-023-02860-4. Epub 2023 Jul 11.
7
The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.癌症患者静脉血栓栓塞预测的 Khorana 评分：系统评价和荟萃分析。
Haematologica. 2019 Jun;104(6):1277-1287. doi: 10.3324/haematol.2018.209114. Epub 2019 Jan 3.
8
Provider education program on the Khorana score to promote venous thromboembolism chemoprophylaxis in patients with gynecologic cancer.关于Khorana评分的提供者教育项目，以促进妇科癌症患者的静脉血栓栓塞化学预防。
Int J Gynecol Cancer. 2022 Apr 4;32(4):547-552. doi: 10.1136/ijgc-2021-003125.
9
Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.验证 Khorana 评分在 40218 例开始化疗的癌症患者中预测静脉血栓栓塞的准确性。
Blood Adv. 2022 May 24;6(10):2967-2976. doi: 10.1182/bloodadvances.2021006484.
10
[Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review].[使用科纳纳评分预测静脉血栓栓塞症的发病率：文献综述]
Yakugaku Zasshi. 2021;141(4):611-622. doi: 10.1248/yakushi.20-00228.

引用本文的文献

1
Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival.肺癌患者的血浆组织因子活性可预测静脉血栓栓塞和总体生存率低下。
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102359. doi: 10.1016/j.rpth.2024.102359. eCollection 2024 Feb.
2
Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.运用三种预测模型评估血液系统恶性肿瘤患者静脉血栓栓塞风险。
J Cancer Res Clin Oncol. 2023 Dec;149(20):17771-17780. doi: 10.1007/s00432-023-05475-7. Epub 2023 Nov 7.
3
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
风险导向的肺癌和胃肠道癌门诊血栓预防：TARGET-TP 随机临床试验。
JAMA Oncol. 2023 Nov 1;9(11):1536-1545. doi: 10.1001/jamaoncol.2023.3634.
4
The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.Khorana 评分与接受免疫检查点抑制剂治疗的癌症患者的静脉和动脉血栓形成：一项丹麦队列研究。
J Thromb Haemost. 2022 Dec;20(12):2921-2929. doi: 10.1111/jth.15883. Epub 2022 Oct 7.
5
Prediction models for venous thromboembolism in ambulatory adults with pancreatic and gastro-oesophageal cancer: protocol for systematic review and meta-analysis.门诊成人胰腺和胃食管癌症患者静脉血栓栓塞预测模型：系统评价和荟萃分析的方案。
BMJ Open. 2022 Mar 4;12(3):e056431. doi: 10.1136/bmjopen-2021-056431.
6
Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.验证 Khorana 评分在 40218 例开始化疗的癌症患者中预测静脉血栓栓塞的准确性。
Blood Adv. 2022 May 24;6(10):2967-2976. doi: 10.1182/bloodadvances.2021006484.
7
Thromboembolic risk in patients with lung cancer receiving systemic therapy.肺癌患者接受系统治疗的血栓栓塞风险。
Br J Haematol. 2021 Jul;194(1):179-190. doi: 10.1111/bjh.17476. Epub 2021 Jun 16.
8
Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care.同时接受姑息治疗的癌症患者的静脉血栓栓塞
Cancers (Basel). 2020 May 6;12(5):1167. doi: 10.3390/cancers12051167.
9
Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor-tissue factor axis.在一个小鼠癌症模型中，代谢物通过芳基烃受体-组织因子轴增强静脉血栓形成倾向。
Blood. 2019 Dec 26;134(26):2399-2413. doi: 10.1182/blood.2019001675.
10
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill.高危患者群体（癌症患者和重症患者）静脉血栓栓塞症预防和治疗中未满足的临床需求评估
Thromb J. 2019 Apr 15;17:6. doi: 10.1186/s12959-019-0196-6. eCollection 2019.